Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Supplementary material to: Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

  • Zheng, Kang
  • Hao, Fengjie
  • Medrano-García, Sandra
  • Chen, Chaobo
  • Guo, Feifei
  • Morán-Blanco, Laura
  • Rodríguez-Perales, Sandra
  • Torres-Ruiz, Raúl
  • Peligros, María Isabel
  • Vaquero, Javier
  • Bañares, Rafael
  • Gómez del Moral, Manuel
  • Regueiro, José R.
  • Martínez-Naves, Eduardo
  • Ramadan Mohamed, Mohamed
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Gilbert-Ramos, Albert
  • Guixé-Muntet, Sergi
  • Fernández-Iglesias, Anabel
  • Gracia-Sancho, Jordi
  • Coll, Mar
  • Graupera, Isabel
  • Ginès, Pere
  • Ciudin, Andreea
  • Rivera-Esteban, Jesús
  • Pericàs, Juan M.
  • Frutos, María Dolores
  • Ramos-Molina, Bruno
  • Herranz, José María
  • Ávila, Matías A.
  • Nevzorova, Yulia A.
  • Fernández-Malavé, Edgar
  • Cubero, Francisco Javier
Supplementary methods, tables (1-4) and figures legends (1-10)., Progressive hepatic damage and fibrosis are major features of chronic liver diseases of different etiology, yet the underlying molecular mechanisms remain to be fully defined. N-RAS, a member of the RAS family of small guanine nucleotide-binding proteins also encompassing the highly homologous H-RAS and K-RAS isoforms, was previously reported to modulate cell death and renal fibrosis; however, its role in liver damage and fibrogenesis remains unknown. Here, we approached this question by using N-RAS deficient (N-RAS−/−) mice and two experimental models of liver injury and fibrosis, namely carbon tetrachloride (CCl4) intoxication and bile duct ligation (BDL). In wild-type (N-RAS+/+) mice both hepatotoxic procedures augmented N-RAS expression in the liver. Compared to N-RAS+/+ counterparts, N-RAS−/− mice subjected to either CCl4 or BDL showed exacerbated liver injury and fibrosis, which was associated with enhanced hepatic stellate cell (HSC) activation and leukocyte infiltration in the damaged liver. At the molecular level, after CCl4 or BDL, N-RAS−/− livers exhibited augmented expression of necroptotic death markers along with JNK1/2 hyperactivation. In line with this, N-RAS ablation in a human hepatocytic cell line resulted in enhanced activation of JNK and necroptosis mediators in response to cell death stimuli. Of note, loss of hepatic N-RAS expression was characteristic of chronic liver disease patients with fibrosis. Collectively, our study unveils a novel role for N-RAS as a negative controller of the progression of liver injury and fibrogenesis, by critically downregulating signaling pathways leading to hepatocyte necroptosis. Furthermore, it suggests that N-RAS may be of potential clinical value as prognostic biomarker of progressive fibrotic liver damage, or as a novel therapeutic target for the treatment of chronic liver disease., This work was supported by the MICINN Retos RTI2018-095673-B-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, all of which were co-funded with FEDER funds, AMMF 2018/117, COST Action CA17112 and Comunidad de Madrid S2022/BMD-7409. This project has received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No. 101095679. The research group belongs to the validated Research Groups Ref. 970935 Liver Pathophysiology, 920631 Lymphocyte Immunobiology and IBL-6 (imas12-associated). KZ was supported by the China Scholarship Council. SM-G was supported by a predoctoral scholarship from Complutense University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis

  • Lamas-Paz, Arantza
  • Hionides-Gutiérrez, Alejandro
  • Guo, Feifei
  • Jorquera, Gonzalo
  • Morán-Blanco, Laura
  • Benedé-Ubieto, Raquel
  • Mesquita, Mariana
  • Estévez-Vázquez, Olga
  • Zheng, Kang
  • Mazariegos, Marina
  • Vázquez-Ogando, Elena
  • Blázquez-López, Elena
  • Asensio, Iris
  • Mutlu, Beste
  • Gomez-Santos, Beatriz
  • Peligros, María Isabel
  • Vaquero, Javier
  • Bañares, Rafael
  • Delgado, Teresa C.
  • Martínez-Chantar, María Luz
  • Martínez-Naves, Eduardo
  • Sanz-García, Carlos
  • Mohamed, Mohamed Ramadan
  • Tesolato, Sofía
  • Iniesta, Pilar
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Martínez-Alcocer, Ana
  • Sanfeliu-Redondo, David
  • Fernández-Iglesias, Anabel
  • Gracia-Sancho, Jordi
  • Coll, Mar
  • Graupera, Isabel
  • Ginès, Pere
  • Ciudin, Andrea
  • Rivera-Esteban, Jesús
  • Pericàs, Juan M.
  • Ávila, Matías A.
  • Frutos, Maria Dolores
  • Martínez-Cáceres, Carlos Manuel
  • Ramos-Molina, Bruno
  • Aspichueta, Patricia
  • Puigserver, Pere
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
[Background & Aims] Expression of P21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD); however, the underlying mechanisms remain unknown. In the present study, we investigated the function of CDKN1A in SLD., [Methods] CDKN1A expression levels were evaluated in different patient cohorts with SLD, fibrosis, and advanced chronic liver disease (ACLD). Cdkn1a-/- and Cdkn1a+/+ mice were fed with either a Western diet (WD), a Lieber-DeCarli (LdC) diet plus multiple EtOH (ethanol) binges, or a DuAL diet (metabolic dysfunction-associated fatty liver disease and alcohol-related liver). Primary hepatocytes were isolated and functional assays performed., [Results] A significant increase in CDKN1A expression was observed in patients with steatohepatitis and fibrosis (with a positive correlation with both NAFLD Activity Score and fibrosis staging scores), cirrhosis and ACLD. Cdkn1a+/+ mice, fed a DuAL diet exhibited liver injury and cell death increased reactive oxygen species (ROS), and markers of senescence (γH2AX, β-GAL, Cdkn1a/p53) contributing to steatosis and inflammation. In contrast, Cdkn1a-/- mutant mice showed a significant decrease in senescence-associated markers as well as in markers of liver injury, hepatic steatosis and an increase in fatty acid oxidation and reduction in free fatty acid uptake as well as de novo lipogenesis. Mechanistically, activation of the AMPK-SIRT3 was observed in Cdkn1a-deleted animals., [Conclusions] Cdkn1a deletion protected against preclinical SLD by promoting fatty acid oxidation and preventing free fatty acid uptake and de novo lipogenesis via the AMPK-SIRT3 axis. CDKN1A expression was found to be directly correlated with increased severity of NAFLD Activity Score and fibrosis in patients with SLD. CDKN1A could be a potential theragnostic target for the treatment of metabolic dysregulation in patients with SLD, with and without alcohol consumption., [Impact and implications] Expression of p21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD), but the molecular mechanisms remain elusive. Interestingly, in this study we found that Cdkn1a deletion protected against preclinical SLD by promoting fatty acid oxidation and preventing free fatty acid uptake and de novo lipogenesis, via the AMPK-SIRT3 axis. Translationally, Cdkn1a expression was found to be directly correlated with increased severity of NAFLD Activity Score (NAS) and fibrosis in SLD patients, and therefore, CDKN1A might be used potential theragnostic target for the treatment of metabolically induced SLD, with and without alcohol consumption., This work was supported by the MICIU/AEI/10.13039/501100011033 PID2020-113299RA-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, PID2021-124425OB-I00, PID2023-150260OB-I00, and PID2023-151347OB-I00, all of which were co-financed with Fondos FEDER, UE, Basque Government, Department of Education (IT1476-2), the Institute of Health Carlos III (ISCIII) (awards numbers PI20/00505 and PI23/00171), EXOHEP2-CM (S2022/BMD-7409), HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 and the Dynamic Resilience Program - Wellcome Leap. CSG is an Atracción de Talento (CAM) 2019 2019-T1/BMD-13313. The research group belongs to the validated Research Groups Ref. 970935 ‘Liver Pathophysiology’, 920631 ‘Lymphocyte immunobiology’, 920361 ‘Inmunogenética e inmunología de las mucosas’ and IBL-6 (imas12-associated). ALP and AH are recipients of a UCM Real Colegio Complutense (RCC) Harvard - Santander scholarships CT17/17 and CT15/23, respectively. BRM is supported by the ‘Miguel Servet Type I’ program (CP19/00098, funded by the Institute of Health Carlos III, Spain; co-funded by the ‘Fondo Europeo de Desarrollo Regional’)., Peer reviewed